Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Degron Therapeutics Inc.

Headquarters: Shanghai, China
Year Founded: 2021
Status: Private

BioCentury | Oct 31, 2024
Deals

Trend watch: Degrader deals show glues are sticking

At least seven molecular glue degrader deals announced this year; less deal activity for classical PROTACs
BioCentury | May 29, 2024
Deals

Deals Report: Three $1B+ takeouts highlight demand in immunology, renal

Plus: Takeda-Degron to develop molecular glue degraders; Lilly-Aktis collaborate on radiopharmaceuticals; and more 
BioCentury | May 23, 2024
Product Development

Amphista degrades a cancer target using a non-traditional ligase

Amphista’s targeted glues combine the advantages of PROTACs and molecular glues to create selective, orally bioavailable therapies
BioCentury | Nov 11, 2022
Product Development

Molecular glue degraders: moving beyond IMiDs

Technologies unraveling the relationships between glue structures and conformational changes are opening up new targets and E3 ligases
BioCentury | Jun 10, 2022
Finance

June 9 Quick Takes: Venture rounds for Tessa, Degron, Ancora, Charm and Relation

Plus Arnay partners with Alloy and updates from DBV and more
Items per page:
1 - 5 of 5